Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194881 | PMC |
| http://dx.doi.org/10.4300/JGME-D-18-00640.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amphibian cellular immune response to chytridiomycosis at metamorphic climax.
Immunol Res
January 2025
School of Environment and Science, Griffith University, Southport, QLD, 4222, Australia.
The fungal disease chytridiomycosis (caused by Batrachochytrium dendrobatidis [Bd]) is a primary contributor to amphibian declines. The frog metamorphic stages, characterised by extensive physiological reorganisation and energy expenditure, have heightened susceptibility to Bd. However, little is known about how these metamorphic stages respond immunologically to Bd infection.
View Article and Find Full Text PDFCareer Planning and Maintaining Well-being in Academic Plastic Surgery.
Plast Reconstr Surg Glob Open
January 2025
Department of Plastic and Reconstructive Surgery, The Ohio State University, College of Medicine, Wexner Medical Center, Columbus, OH.
Success in academic plastic surgery is based on the traditional pillars of promotion: clinical excellence, teaching, research, leadership, and service to the university and community. The time commitment and workload for career advancement are highly demanding and, therefore, well-being is essential to avoid burnout. A congruent healthy work environment that meets institutional goals and surgeons' objectives can be established through inclusive, transparent, strategic, and operational planning.
View Article and Find Full Text PDFXanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes.
Pharmacopsychiatry
January 2025
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson-Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo.
View Article and Find Full Text PDFThe CHIPOR trial-sufficient evidence to use hyperthermic intraperitoneal chemotherapy in routine care for recurrent ovarian cancer?
Int J Gynecol Cancer
January 2025
Military Hospital Satwari, Department of Obstetrics and Gynaecology, Jammu, India. Electronic address:
Implicit bias assessment by career stage in medical education training: a narrative review.
BMC Med Educ
January 2025
University of Illinois Chicago, College of Medicine, Associate Professor of Medicine, Chicago, IL, US.
Implicit biases involve associations outside conscious awareness that lead to a negative evaluation of a person based on individual characteristics. Early evaluation of implicit bias in medical training can prevent long-term adverse health outcomes related to racial bias. However, to our knowledge, no present studies examine the sequential assessment of implicit bias through the different stages of medical training.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!